TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24076689

Group type: EXPERIMENTAL
Intervention: External valvuloplasty for small subcutaneous veins
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional procedures (control group)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Patients with venous reflux
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Patients without venous reflux
Number of subjects: 39
Study: 21880848

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D (1 g Ca/400 IU vitamin D daily)
Number of subjects: 36482
Study: 20027426

Group type: EXPERIMENTAL
Intervention: Green tea rinse (1 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water rinse (control, 1 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ERO+I-ABR (immediate toothbrushing after erosion)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ERO+30-min-ABR (toothbrushing 30 min after erosion)
Number of subjects: 10
Study: 16446329

Group type: EXPERIMENTAL
Intervention: 90Y‐muHMFG1 plus standard treatment
Number of subjects: 447

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 447
Study: 15242142

Group type: EXPERIMENTAL
Intervention: Nonorganizational religiosity
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intrinsic religiosity
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Low religiosity
Number of subjects: 91

Group type: COMPARATOR
Intervention: Religiosity or spirituality
Number of subjects: 91
Study: 11866284

Group type: EXPERIMENTAL
Intervention: High dose HBV vaccination (40 microg administered monthly for 3 months)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: High dose HBV vaccination (booster dose of 80 microg for nonresponders)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (26 individuals with no evidence of liver disease receiving the same vaccination schedule)
Number of subjects: 152
Study: 9642936

Group type: EXPERIMENTAL
Intervention: One dose of inactivated influenza vaccine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Two doses of inactivated influenza vaccine
Number of subjects: 71
Study: 8083453

Group type: EXPERIMENTAL
Intervention: Methotrexate (15 mg weekly)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2576861

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 287
Study: 335348

Group type: EXPERIMENTAL
Intervention: H. influenzae type b vaccine
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Control group (group A meningococcal vaccine)
Number of subjects: 100000
Study: 28598446

Group type: EXPERIMENTAL
Intervention: Workshop on construction of MCQs
Number of subjects: 16
Study: 26456573

Group type: EXPERIMENTAL
Intervention: Paclitaxel 90 mg/m² IV (days 1, 8, and 15) and bevacizumab 10 mg/kg IV (days 1, 15) with everolimus 10 mg daily (Arm 1)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Paclitaxel 90 mg/m² IV (days 1, 8, and 15) and bevacizumab 10 mg/kg IV (days 1, 15) with placebo (Arm 2)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both arms (Arm 1 and Arm 2)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Arm 1 (everolimus)
Number of subjects: 113
Study: 23245582

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg IV iron sucrose
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg IV iron sucrose
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg IV iron sucrose
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: All dosing regimens
Number of subjects: 145
Study: 21273758

Group type: EXPERIMENTAL
Intervention: Compact catheter
Number of subjects: 28

Group type: COMPARATOR
Intervention: Regular catheter
Number of subjects: 28
Study: 19393845

Group type: EXPERIMENTAL
Intervention: ketoprofen 100 mg + acetaminophen 1000 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: acetaminophen 1000 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: ketoprofen 100 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 76
Study: 17078155

Group type: EXPERIMENTAL
Intervention: Losartan-based antihypertensive treatment
Number of subjects: 204

Group type: COMPARATOR
Intervention: Atenolol-based antihypertensive treatment
Number of subjects: 204
Study: 15669418

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone (IV bolus of 2mg/kg in 15 minutes, followed by maintenance infusion of 0.0067 mg/kg/min until conversion to sinus rhythm or for up to 90 minutes)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (matching saline solution administered in the same fashion)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone
Number of subjects: 75
Study: 11211369

Group type: EXPERIMENTAL
Intervention: Imipramine combined with cognitive-behavioral therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo combined with cognitive-behavioral therapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Overall treatment (including psychotropic medication and outpatient therapy)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Baseline somatic complaints
Number of subjects: 63
Study: 9368196

Group type: EXPERIMENTAL
Intervention: Citalopram infusion (20 mg i.v. at 14:20-14:50 h) after a night of undisturbed sleep
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Citalopram infusion (20 mg i.v. after a night of sleep deprivation
Number of subjects: 7
Study: 28895428

Group type: EXPERIMENTAL
Intervention: Clodronate (10 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (10 patients, control group)
Number of subjects: 20
Study: 27537603

Group type: EXPERIMENTAL
Intervention: Kestose, administered orally every day for 12 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 65
Study: 25903295

Group type: EXPERIMENTAL
Intervention: Unfiltered results
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-pass filters with cutoffs at 0.3 Hz and above
Number of subjects: 0
Study: 24330422

Group type: EXPERIMENTAL
Intervention: Vitamin A (100,000 IU for infants <12 months & 200,000 IU for children >12 months) and 10 mg daily zinc for 6 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vitamin A and zinc placebo for 6 months
Number of subjects: 200
Study: 20218404

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mononarcosis with ketamine
Number of subjects: 0
Study: 17383342

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) for 3 weeks before surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15102997

Group type: EXPERIMENTAL
Intervention: Uracil-tegafur (250 mg of tegafur per square meter of body-surface area per day) for two years
Number of subjects: 999

Group type: COMPARATOR
Intervention: No treatment (observation)
Number of subjects: 999
Study: 11476795

Group type: EXPERIMENTAL
Intervention: 17alpha-hydroxyprogesterone caproate (17-HPC) 341 mg every 3 days
Number of subjects: 300

Group type: COMPARATOR
Intervention: Intramuscular progesterone (P) 50 mg daily
Number of subjects: 300
Study: 9601347

Group type: EXPERIMENTAL
Intervention: Swaddled condition
Number of subjects: 15

Group type: COMPARATOR
Intervention: Unsaddled condition
Number of subjects: 15
Study: 7975797

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fragmin) - 2500‐5000 anti‐Xa‐units once daily for 10 days
Number of subjects: 130

Group type: COMPARATOR
Intervention: Unfractionated heparin (Liquemin) - 5000 IU two to three times daily for 10 days
Number of subjects: 130

Group type: COMPARATOR
Intervention: Comparison of anti‐Xa‐activity
Number of subjects: 130

Group type: COMPARATOR
Intervention: Other coagulation parameters (antithrombin III, partial thrombin time, thrombin time)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Hematologic parameters and liver enzymes
Number of subjects: 130

Group type: COMPARATOR
Intervention: Heparin induced thrombocytopenia
Number of subjects: 130
Study: 2692199

Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1) - 60 micrograms, 3 ampoules, infused daily over 3 hours for 6 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo - 3 ampoules of alpha-CD, infused daily over 3 hours for 6 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 782624

Group type: EXPERIMENTAL
Intervention: Lincomycin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study: 31525137

Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (RGT) program plus physiotherapy (n=6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual care physiotherapy only (control group; n=6)
Number of subjects: 12
Study: 30054906

Group type: EXPERIMENTAL
Intervention: Adequate hydration with nitrates (isosorbide dinitrate combined with isotonic saline at 1.5 mL/kg/h during perioperative period)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Routine hydration (control group)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Adequate hydration with nitrates
Number of subjects: 394
Study: 28856749

Group type: EXPERIMENTAL
Intervention: TensLess® supplementation
Number of subjects: 13
Study: 25952653

Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention (home BP telemonitors, medication adjustments by pharmacists, lifestyle advice via telephone visits)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Usual care (no telemonitoring intervention)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention
Number of subjects: 403
Study: 23657490

Group type: EXPERIMENTAL
Intervention: Education and peer support (EPS)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Education and peer support with access to an outpatient clinic (EPSOC)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 135
Study: 21720260

Group type: EXPERIMENTAL
Intervention: Ultraviolet B (n = 58)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Ultraviolet A (n = 61)
Number of subjects: 119
Study: 19595382

Group type: EXPERIMENTAL
Intervention: Mediterranean‐like diet
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (2.4 g/d)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Both interventions (diet and n-3 PUFA)
Number of subjects: 563
Study: 17719292

Group type: EXPERIMENTAL
Intervention: HbA1c <4.9%
Number of subjects: 2841

Group type: EXPERIMENTAL
Intervention: HbA1c 4.9%-5.1%
Number of subjects: 2841

Group type: EXPERIMENTAL
Intervention: HbA1c >5.1%
Number of subjects: 2841

Group type: EXPERIMENTAL
Intervention: History of diabetes
Number of subjects: 2841

Group type: EXPERIMENTAL
Intervention: Increase in HbA1c level
Number of subjects: 2841

Group type: EXPERIMENTAL
Intervention: Well-known diabetes
Number of subjects: 2841
Study: 15549977

Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography (TE) measurements through various methods (aortic, mitral, pulmonary valves, etc.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Eyeball guessing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Best transoesophageal echocardiography measurements (transaortic measurements using triangular shape assumption)
Number of subjects: 30
Study: 11566079

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine (15 mg) plus fentanyl (25 microgram)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine (15 mg) alone
Number of subjects: 20
Study: 9556011

Group type: EXPERIMENTAL
Intervention: Exosurf
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: ALEC
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Survanta
Number of subjects: 83
Study: 7608841

Group type: EXPERIMENTAL
Intervention: Freeze-dried dura mater membrane
Number of subjects: 69
Study: 2979276

Group type: EXPERIMENTAL
Intervention: Liquid antacid (neutralizing capacity 120 mmol per day)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 1 g cimetidine
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo pain tablets
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 4 weeks of therapy (general)
Number of subjects: 125
Study: 31430366

Group type: EXPERIMENTAL
Intervention: Antibiotic Review Kit (ARK) intervention
Number of subjects: 0
Study: 28251937

Group type: EXPERIMENTAL
Intervention: Cheese diet (SFA: 12.4-12.6% of calories)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Butter diet (SFA: 12.4-12.6% of calories)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cheese diet
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Butter diet
Number of subjects: 92

Group type: COMPARATOR
Intervention: Carbohydrate diet (fat: 25%, SFAs: 5.8%)
Number of subjects: 92

Group type: COMPARATOR
Intervention: MUFA-rich diet (SFAs: 5.8%, MUFAs: 19.6%)
Number of subjects: 92

Group type: COMPARATOR
Intervention: PUFA-rich diet (SFAs: 5.8%, PUFAs: 11.5%)
Number of subjects: 92

Group type: COMPARATOR
Intervention: All diets
Number of subjects: 92
Study: 25546444

Group type: EXPERIMENTAL
Intervention: 1 SET
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3 SETS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 5 SETS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 23543264

Group type: EXPERIMENTAL
Intervention: Increased FV consumption (≥ 5 portions/day) for 16 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Normal diet (≤ 2 portions/day)
Number of subjects: 83
Study: 20528109

Group type: EXPERIMENTAL
Intervention: ADDED (dietary plus physical activity change)
Number of subjects: 29

Group type: COMPARATOR
Intervention: STANDARD (primarily dietary change)
Number of subjects: 29
Study: 19339043

Group type: EXPERIMENTAL
Intervention: 3-unit fiber-reinforced resin composite (FRC) fixed partial dentures (FPDs)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Surface FPDs with additional mechanical retention
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Surface FPDs
Number of subjects: 52
Study: 17294208

Group type: EXPERIMENTAL
Intervention: Radiofrequency assisted uvulopalatoplasty (RAUP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Submucosal channeling of the palate
Number of subjects: 40
Study: 14991374

Group type: EXPERIMENTAL
Intervention: Risperidone and celecoxib
Number of subjects: 50

Group type: COMPARATOR
Intervention: Risperidone and placebo
Number of subjects: 50
Study: 11229946

Group type: EXPERIMENTAL
Intervention: Modified consent form (MF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard industry consent form (IF)
Number of subjects: 100
Study: 9513749

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) infusion of TRP 100 mg/kg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham depletion
Number of subjects: 38
Study: 7921460

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 109

Group type: COMPARATOR
Intervention: T-piece trials
Number of subjects: 109

Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 109
Study: 3050616

Group type: EXPERIMENTAL
Intervention: Defibrotide (800 mg/i.v.)
Number of subjects: 2250

Group type: COMPARATOR
Intervention: Calcium heparin (15,000 UI/s.c.)
Number of subjects: 2250

Group type: EXPERIMENTAL
Intervention: Defibrotide (800 mg/i.v.) and Calcium heparin (15,000 UI/s.c.)
Number of subjects: 2250
Study: 31619463

Group type: EXPERIMENTAL
Intervention: Copanlisib 0.4 mg/kg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Copanlisib 0.8 mg/kg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Copanlisib (both doses)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Adverse events (all grade)
Number of subjects: 63
Study: 31257614

Group type: EXPERIMENTAL
Intervention: Risankizumab 18 mg SC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risankizumab 90 mg SC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risankizumab 300 mg SC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risankizumab 200 mg IV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risankizumab 600 mg IV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risankizumab 1200 mg IV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risankizumab 75 mg SC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg SC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risankizumab (various doses)
Number of subjects: 0
Study: 29912798

Group type: EXPERIMENTAL
Intervention: encenicline 1 mg twice daily
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: encenicline 1 mg twice daily + NRT patch
Number of subjects: 160

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160

Group type: COMPARATOR
Intervention: placebo + NRT patch
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: encenicline alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: encenicline plus placebo patch
Number of subjects: 160
Study: 26821699

Group type: EXPERIMENTAL
Intervention: 5 min guided warm-up using a bronchoscopy simulator
Number of subjects: 33

Group type: COMPARATOR
Intervention: No warm-up
Number of subjects: 33
Study: 24469546

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Minimum Intervention (MI) group
Number of subjects: 180
Study: 23197664

Group type: EXPERIMENTAL
Intervention: UC-MSC transfusions
Number of subjects: 43

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 43
Study: 20221834

Group type: EXPERIMENTAL
Intervention: Minimally invasive anterolateral approach
Number of subjects: 38

Group type: COMPARATOR
Intervention: Modified direct lateral approach
Number of subjects: 38
Study: 17667331

Group type: EXPERIMENTAL
Intervention: Investigational coformulation of EFV/FTC/TDF (test)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Commercially available individual dosage forms (reference treatment)
Number of subjects: 48
Study: 15780109

Group type: EXPERIMENTAL
Intervention: B vitamin supplementation (1 mg of folic acid, 10 mg pyridoxal 5'-phosphate, and 6 µg of vitamin B12)
Number of subjects: 804

Group type: COMPARATOR
Intervention: Dietary protein intake
Number of subjects: 804
Study: 12208584

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 1572
Study: 10221213

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (cetrorelix)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GnRH agonist (buserelin)
Number of subjects: 0
Study: 7797602

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg/day, oral)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 2355822

Group type: EXPERIMENTAL
Intervention: Neck cooling
Number of subjects: 10

Group type: COMPARATOR
Intervention: No neck cooling (control)
Number of subjects: 10
Study: 759664

Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple mastectomy followed by radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wide excision followed by radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast cancer treatment
Number of subjects: 0
Study: 31957177

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 16
Study: 31071131

Group type: EXPERIMENTAL
Intervention: NorVold Abuse Questionnaire (NorAQ) for emotional violence
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: NorVold Abuse Questionnaire (NorAQ) for sexual and/or physical violence
Number of subjects: 1503
Study: 28763451

Group type: EXPERIMENTAL
Intervention: Stepped-care program delivered by trained practice nurses over one year, consisting of watchful waiting, guided self-help, problem solving treatment, and referral to the general practitioner.
Number of subjects: 236

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Stepped-care program (intervention).
Number of subjects: 236
Study: 26469750

Group type: EXPERIMENTAL
Intervention: DHA supplementation (30 mg DHA/kg/d)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 23953830

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional venography
Number of subjects: 30
Study: 22035986

Group type: EXPERIMENTAL
Intervention: TARGET (trauma affect regulation: guide for education and therapy)
Number of subjects: 146

Group type: COMPARATOR
Intervention: PCT (present centered therapy)
Number of subjects: 146

Group type: COMPARATOR
Intervention: WL (wait-list)
Number of subjects: 146
Study: 18957532

Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin daily for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17276670

Group type: EXPERIMENTAL
Intervention: lidocaine 1.5% with epinephrine 1:200000
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: lidocaine 1.5% with epinephrine 1:200000 and 8.4% sodium bicarbonate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: lidocaine 1.5% with 8.4% sodium bicarbonate
Number of subjects: 80
Study: 15531767

Group type: EXPERIMENTAL
Intervention: Trandolapril at a target dose of 4 mg per day
Number of subjects: 8290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8290
Study: 11309014

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg/kg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 and 0.9 mg/kg
Number of subjects: 108
Study: 9444014

Group type: EXPERIMENTAL
Intervention: Mebendazole 25 mg single dose
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Mebendazole 50 mg single dose
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Mebendazole 75 mg single dose
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Mebendazole 100 mg twice daily for 3 days
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg single dose
Number of subjects: 315
Study: 7878597

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine, buspirone, doxepin
Number of subjects: 0